Selumetinib-d4 NEW

Selumetinib-d4；2364350-70-7

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com

• 
  

• Product Information

• Product Number: S041029

• English Name: Selumetinib-d4

• English Alias: Selumetinib-d4

• CAS Number: 2364350-70-7

• Molecular Formula: C₁₇H₁₁D₄BrClFN₄O₃

• Molecular Weight: 461.71

• Advantages

• As a deuterated derivative of Selumetinib, this compound has the following advantages:
• 
  

• Stable structure with clear labeling: Contains 4 deuterium (D) atoms at specific positions, with a molecular weight 4 units higher than Selumetinib. It can be accurately distinguished via mass spectrometry (MS) by characteristic ion peaks (m/z 462 [M+H]⁺), serving as a stable internal standard for quantitative analysis;

• Low isotopic effect: C-D bonds at deuterated sites (e.g., methyl or methylene groups) are more stable than C-H bonds, minimizing hydrogen-deuterium exchange during in vitro/in vivo metabolism and ensuring accurate quantification;

• High detection sensitivity: Combined with LC-MS/MS, the specific isotopic response of deuterated analogs enables precise quantification of Selumetinib in biological samples (e.g., plasma, tissues) at trace levels (ng/mL), reducing matrix interference.

• Applications

• Pharmacokinetic studies: Used as an internal standard in LC-MS/MS methods to quantify Selumetinib concentrations in blood, tissues, and excreta, supporting dose optimization and metabolic pathway analysis;

• Bioavailability assessment: Comparing in vivo exposure of Selumetinib across formulations (tablets, capsules) using deuterated internal standard data to evaluate bioavailability differences;

• Metabolite identification: Assisting in the characterization of oxidative or hydrolytic metabolites by comparing retention times and fragmentation patterns with the deuterated standard.

• Background Description

• Selumetinib, a MEK1/2 inhibitor for plexiform neurofibromatosis in children, requires precise pharmacokinetic characterization to ensure efficacy and safety. Deuterated derivatives like Selumetinib-d4, with similar physicochemical properties to the parent drug but distinct mass spectral signals, are critical as internal standards to enhance accuracy in bioanalytical methods, enabling reliable quantification in complex biological matrices.

• Research Status

• Current research focuses on:
• 
  

• Method validation: Developing LC-MS/MS assays with Selumetinib-d4 as internal standard, achieving quantification limits as low as 0.1 ng/mL for clinical sample analysis;

• Isotope effect evaluation: Confirming minimal impact of deuteration on Selumetinib’s metabolism via in vitro liver microsome studies, validating internal standard suitability;

• Clinical assay standardization: Implementing deuterated internal standard-based methods in multi-center trials to reduce inter-laboratory variability in pharmacokinetic data;

• Formulation development: Using quantitative results with Selumetinib-d4 to optimize drug solubility and dissolution rate in oral formulations, improving bioavailability.

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com